Vol.

No.

January 06, 2023Jan 06, 2023

DOWNLOAD THE PDF

Cover Story

What Ruben Mesa is thinking as he steps into one of the most-watched jobs in cancer

Ruben A. Mesa is going into the new year with a massive new challenge: bring together the programs and cultures of an academic cancer center and a hybrid cancer center—and convincing NCI that the new organization should keep its elite designation.

Free Guest Editorial

A New Year’s greeting from Ukraine

By Andriy Beznosenko

Capitol Hill

NIH, NCI budgets up by more than 5% in FY23; FDA gets more robust accelerated approval authority

By Matthew Bin Han Ong

Free In the Archives

NCI oral history: J. Palmer Saunders on being tasked to investigate NCI’s Chemotherapy Program

In Brief

Medicare and insurance changes remove barriers for stool-based CRC screening

Sheri Robb named Walther Professor in Supportive Oncology at Indiana University

Lucia Borriello named assistant professor at Temple

Zachary J. Roberts named executive vice president of R&D at Allogene

Funding Opportunities

FDA issues RFA to improve health equity in oncology therapeutic development

Clinical Roundup

First DKMS clinical trial show practice-changing results for patients with AML

Medicaid expansion improves cancer survival outcomes for young adults, Winship study finds

Phase III trial of TAVT-45 in metastatic prostate cancer yields positive top-line results

Phase III trial of zanidatamab in biliary tract cancers produces positive topline data

Oral paclitaxel combination shows positive results for TNBC subgroup in phase II study

UTSW-led study shows promise for upper urinary tract cancer drug

UTSW immunologists uncover obesity-linked trigger to severe form of liver disease

Interim results from OPTIMIZE-1 phase II study show >50% ORR in pancreatic cancer

IU research points to a biomarker for cardiotoxicity in breast cancer–and a role for dexamethasone

Drugs & Targets

FDA grants accelerated approval to Lunsumio for R/R follicular lymphoma

FDA approves first gene therapy for high-risk, non-muscle-invasive bladder cancer

FDA approves imaging drug to help identify lung cancer lesions

FDA accepts supplemental BLAs for Padcev + Keytruda for urothelial cancer

Panel submits operational evaluation of FDA’s tobacco program

EC approves allogeneic T-cell immunotherapy in rare cancer

Caris and Xencor expand collaboration for XmAb antibody drug candidates

C2i Genomics, AstraZeneca to collaborate on MRD test for clinical R&D

Mersana to collaborate with Merck KGaA to develop ADCs

Gilead to acquire remaining rights to immunotherapy GS-1811 from Jounce

NCI Trials

NCI Trials for January 2023

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE